Once-daily dosage lamivudine another ARV first for Cipla Medpro

Once-daily dosage lamivudine another ARV first for Cipla Medpro

No abstract available.

Saved in:

Bibliographic Details
Main Author:	Editorial Office
Format:	Article
Language:	English
Published:	AOSIS 2008-02-01
Series:	South African Family Practice
Online Access:	https://safpj.co.za/index.php/safpj/article/view/1078
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease
by: Ji Young Yun, et al.
Published: (2017-01-01)

RP-HPLC method development and validation of Abacavir, Lamivudine and Zidovudine in combined pharmaceutical dosage by analytical QbD
by: Divyesh Vanparia, et al.
Published: (2025-04-01)

Extended Efficacy of Once-Daily Atomoxetine in ADHD
by: J Gordon Millichap
Published: (2004-07-01)

Hvem skal arve hytta?
by: Marianne E. Lien, et al.
Published: (2018-01-01)

QUANTITATION OF LAMIVUDINE BY UV SPECTROPHOTOMETRY
by: Y. A. Gonchikova, et al.
Published: (2017-07-01)

Ķirurgs un rakstnieks Arvēds Alksnis
by: Vīksna, Arnis
Published: (1999-01-01)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.
by: Catherine G Derington, et al.
Published: (2020-01-01)

Once-Daily Aminoglycoside Dosing: A New Look at an Old Drug
by: JM Conly, et al.
Published: (1994-01-01)

Correlation of Side Effects of ARV (Antiretroviral) Drugs with ARV Therapy Compliance in PLWHA at KDS Jombang Care Center Plus of Jombang Regency
by: Riska Putri Dessyanti, et al.
Published: (2024-08-01)

Compatibility Study of Lamivudine with Various Cellulose Polymers
by: P. Narayana Raju, et al.
Published: (2009-01-01)

Arv1; a “Mover and Shaker” of Subcellular Lipids
by: J. Jose Corbalan, et al.
Published: (2025-01-01)

Aulestads besværlige arv: «Godviljens høvdingsete» og «nazireir»
by: Marianne Egeland
Published: (2018-11-01)

Safety of ilunocitinib tablets (Zenrelia™) after once daily oral administration in dogs
by: Emmanuelle A. Kuntz, et al.
Published: (2025-03-01)

Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients
by: Maria Anastasia Bianchini, et al.
Published: (2010-06-01)

Successful lamivudine therapy for chronic hepatitis B in the family
by: Nožić Darko
Published: (2006-01-01)

Once‐Weekly Insulin Versus Once‐Daily Insulin for Type 1 Diabetes Treatment: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Obieda Altobaishat, et al.
Published: (2025-05-01)

ARV Nonlinear Disturbance Estimation Based on Extended State Observer
by: Xiaohan LIU, et al.
Published: (2025-06-01)

Om sjukdom, arv och miljö i gamla källor
by: Ulf Drugge
Published: (1992-06-01)

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.
by: Jean-Guy Baril, et al.
Published: (2016-01-01)

Nail the diagnosis: Lamivudine-induced periungual pyogenic granulomas in PLHIV
by: Karthick Kumar Vaitheeswaran, et al.
Published: (2025-01-01)

A randomised double-blind crossover study: once-daily low-dose prednisolone compared with thrice-daily hydrocortisone in adrenal insufficiency
by: Sirazum Choudhury, et al.
Published: (2025-07-01)

Long-term outcomes of three distinct once-daily schedules for accelerated partial breast irradiation
by: Lorenzo Vinante, et al.
Published: (2025-06-01)

Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
by: Ikuko Tanaka, et al.
Published: (2013-01-01)

Outcomes of a young ARV clinic within an established Family Practice
by: Zandy Rosochacki, et al.
Published: (2009-02-01)

THE COST OF SMS REMINDER TO IMPROVE ARV ADHERENCE AMONG KEY POPULATIONS
by: Mery Nurma Juwita, et al.
Published: (2024-12-01)

The Arve Valley and Environmental Health: From Therapeutic Imagination to Eco-anxiety
by: Alexandre Savioz
Published: (2023-03-01)

LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING
by: Jassada Buaboonnam, et al.
Published: (2021-10-01)

Reprofiling lamivudine as an antibiofilm and anti-pathogenic agent against Pseudomonas aeruginosa
by: Othman Yahya Alyahyawy, et al.
Published: (2025-02-01)

Treatment of subacute hepatitis B with lamivudine: A pilot study in Serbia
by: Delić Dragan, et al.
Published: (2009-01-01)

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
by: Florian Stehling, et al.
Published: (2017-01-01)

Omeprazole Once or Twice Daily with Clarithromycin and Metronidazole for Helicobacter pylori Eradicaiton in a Canadian Community Practice
by: Naoki Chiba, et al.
Published: (2000-01-01)

IL-1RN and IL-1β Polymorphism and ARV-Associated Hepatotoxicity
by: HariOm Singh, et al.
Published: (2018-01-01)

Assessing Medication Adherence to Tadalafil 5 mg Once Daily in Erectile Dysfunction: A Cross‐Sectional Analysis
by: Emre Kandemir, et al.
Published: (2025-06-01)

Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation
by: P. N. Vlasov
Published: (2017-11-01)

Evaluation of cytokine levels in HIV-infected individuals on therapy with tenofovir, lamivudine, and dolutegravir
by: C.D. da Silva-Junior, et al.
Published: (2025-05-01)

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART
by: Jennifer K. van Heerden, et al.
Published: (2025-04-01)

Development and Characterization of Printlets of Lamivudine for Pediatric Patients Using Selective Laser Sintering
by: Canberk Kayalar, et al.
Published: (2025-03-01)

The World As It Once Was
by: Kees Rookmaaker
Published: (2021-10-01)

Ontologisk stratifisering: En komparasjon av californisk genetisk arv og kaluliske ånder
by: Martin Eggen Mogseth
Published: (2021-01-01)

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.
by: Laurent Cotte, et al.
Published: (2017-01-01)